<DOC>
	<DOCNO>NCT02687087</DOCNO>
	<brief_summary>The purpose study evaluate clinical safety effectiveness Visco-ease dry mouth spray treatment Radiotherapy Induced Xerostomia ( RIX ) head neck cancer patient . A parallel group double blind study design select . The primary outcome change GRIX score baseline ( visit 1 ) end treatment ( visit 7 ) . The primary outcome compare Visco-ease placebo treatment .</brief_summary>
	<brief_title>A Study Patients With Dry Mouth Sticky Saliva During Radiotherapy</brief_title>
	<detailed_description />
	<mesh_term>Xerostomia</mesh_term>
	<criteria>1 . Subject provide write informed consent 2 . Male female subject ≥ 18 year age 3 . Subjects prescribe radiotherapy chemoradiotherapy primary treatment head neck tumours one parotid glands receive significant dose radiation judge CI PI radiotherapy planning process 1 . Subject pregnant breastfeeding 2 . Subjects know allergy egg , soya , lanolin ( sheep 's wool grease ) base product 3 . Subjects history autoimmune disease pretreatment xerostomia ( e.g . Sjögren 's syndrome ) underlie systemic illness know cause xerostomia independent prior radiation therapy exposure 4 . Subjects participate investigational medicinal product study within 30 day prior sign consent 5 . Any clinically significant disease condition may interfere study treatment outcome study ( discretion CI PI ) 6 . Subjects unable independently complete questionnaire diary 7 . Subjects judge inappropriate inclusion study CI PI 8 . Subjects head neck cancer surgery primary site . Neck dissection alone exclusion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Radiotherapy Induced Xerostomia ( RIX )</keyword>
</DOC>